Lux Health Tech Acquisition Corp. Warrants
LUXAW
LUXAW was delisted on the 28th of October, 2022.
0 hedge funds and large institutions have $0 invested in Lux Health Tech Acquisition Corp. Warrants in 2022 Q4 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 33 closing their positions.
100% less funds holding
Funds holding: 34 → 0 (-34)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
100% less capital invested
Capital invested by funds: $1.39M → $0 (-$1.39M)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 33
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
Radcliffe Capital Management
Bala Cynwyd,
Pennsylvania
|
-$668K |
| 2 |
SCM
Shaolin Capital Management
Miami,
Florida
|
-$113K |
| 3 |
CAC
Cowen and Company
New York
|
-$74K |
| 4 |
WH
Wolfswood Holdings
New York
|
-$74K |
| 5 |
Balyasny Asset Management
Chicago,
Illinois
|
-$56K |
LUXAW Hedge Fund Activity: Q4 2022 in Review
0 of the 6,237 institutional investors tracked by Wall St. Rank reported a position in Lux Health Tech Acquisition Corp. Warrants (LUXAW) for Q4 2022, worth a combined $0 — down 100% from $1.39M a quarter earlier.
Sellers outnumbered buyers: 33 funds closed out of LUXAW and 0 opened new positions — a net loss of 33 holders — while 0 trimmed existing stakes and 0 added.
The largest seller was Radcliffe Capital Management, exiting entirely with an estimated $668K sold.
- 0 institutional investors held Lux Health Tech Acquisition Corp. Warrants (LUXAW) as of Q4 2022, down from 34 in Q3 2022.
- Funds reported $0 of Lux Health Tech Acquisition Corp. Warrants stock for Q4 2022, down 100% quarter-over-quarter.
- 0 funds opened new Lux Health Tech Acquisition Corp. Warrants positions in Q4 2022 and 33 closed out, a net change of -33 holders.
- The largest Lux Health Tech Acquisition Corp. Warrants seller in Q4 2022 was Radcliffe Capital Management, an estimated $668K sold.
Based on aggregated 13F filings for Q4 2022.